Skip to main content
Ying Gao on Muck Rack

Ying Gao

As seen in: Environmental Health Perspectives, Color Research & Application, Nature, Wiley Online Library, PLOS ONE, Frontiers, Frontiers in Immunology, MDPI, Taylor & Francis Online, Thorax and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Ying

Contact Ying, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Vulvar angiomyofibroblastoma misdiagnosed as subcutaneous lipoma: a case report and literature review

|
By Di Liu, Ying Gao
| Frontiers
Abstract Background: Angiomyofibroblastoma (AMFB) of the vulva is a rare benign mesenchymal tumor of the vulva that affects the vulva and vagina of adult women. Often mimicked by other vulvar masses such as vestibular macrocystic glands, subcutaneous lipomas, and dermoid cysts, AMFB can be detected by histopathology. Here, we present a case where AMFB was initially misdiagnosed as a subcutaneous lipoma.
Open in Who Shared Issue with article?

Immunomodulation for stroke-associated pneumonia: a systematic review of mechanistic insight and emerging therapeutic strategies in animal models

|
By Xiangyun Chen, Yihe Xu, Yonghong Gao, Xinxing Lai, Rufan Xu, Hongrui Zhang, Zhenhong Liu, Ying Gao
| Frontiers in Immunology
Abstract Backgrounds and aims: Stroke-associated pneumonia (SAP) is a major infectious complication that increases mortality after stroke. Stroke-induced immunosuppression has been proposed as a key driver of SAP, supporting the rationale for immunomodulation. This review systematically outlines the immunopathology of SAP and evaluates immune-targeted strategies.
Open in Who Shared Issue with article?

Marked and reversible circulating insulin-like growth factor-1 elevation during teprotumumab N01 treatment for thyroid eye disease with limited correspondence to glycemic changes

|
By Wei Zhao, Lingli Zhou, Ying Gao, Xianghai Zhou, Xueyao Han, Xiuying Zhang, Linong Ji
| Frontiers
Abstract Background: Insulin-like growth factor-1 (IGF-1) receptor (IGF-1R) inhibitors have changed the treatment landscape for moderate-to-severe thyroid eye disease (TED), but the longitudinal behavior of circulating IGF-1 during and after therapy remains insufficiently characterized. This study aimed to describe serum IGF-1 dynamics in patients with TED treated with IGF-1R inhibitor teprotumumab N01 and to explore their relationship with glycemic changes.
Open in Who Shared Issue with article?
See all 254 licensed articles (277 Total)